Literature DB >> 25068787

The role of cytokines in breast cancer development and progression.

Marcela Esquivel-Velázquez1, Pedro Ostoa-Saloma, Margarita Isabel Palacios-Arreola, Karen E Nava-Castro, Julieta Ivonne Castro, Jorge Morales-Montor.   

Abstract

Cytokines are highly inducible, secretory proteins that mediate intercellular communication in the immune system. They are grouped into several protein families that are referred to as tumor necrosis factors, interleukins, interferons, and colony-stimulating factors. In recent years, it has become clear that some of these proteins as well as their receptors are produced in the organisms under physiological and pathological conditions. The exact initiation process of breast cancer is unknown, although several hypotheses have emerged. Inflammation has been proposed as an important player in tumor initiation, promotion, angiogenesis, and metastasis, all phenomena in which cytokines are prominent players. The data here suggest that cytokines play an important role in the regulation of both induction and protection in breast cancer. This knowledge could be fundamental for the proposal of new therapeutic approaches to particularly breast cancer and other cancer-related disorders.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25068787      PMCID: PMC4291218          DOI: 10.1089/jir.2014.0026

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  220 in total

Review 1.  Lymphokines and the immune response: the central role of interleukin-2.

Authors:  S L Swain
Journal:  Curr Opin Immunol       Date:  1991-06       Impact factor: 7.486

2.  Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist.

Authors:  L J Miller; S H Kurtzman; K Anderson; Y Wang; M Stankus; M Renna; R Lindquist; G Barrows; D L Kreutzer
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

3.  Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy.

Authors:  Angela R Starkweather; Debra E Lyon; Christine M Schubert
Journal:  Biol Res Nurs       Date:  2011-11-14       Impact factor: 2.522

Review 4.  Adipokines in inflammation and metabolic disease.

Authors:  Noriyuki Ouchi; Jennifer L Parker; Jesse J Lugus; Kenneth Walsh
Journal:  Nat Rev Immunol       Date:  2011-01-21       Impact factor: 53.106

Review 5.  Significance of interleukin-6 (IL-6) in breast cancer (review).

Authors:  Heike Knüpfer; Rainer Preiss
Journal:  Breast Cancer Res Treat       Date:  2006-08-23       Impact factor: 4.872

Review 6.  Interleukin-6 signaling pathway in targeted therapy for cancer.

Authors:  Yuqi Guo; Feng Xu; TianJian Lu; Zhenfeng Duan; Zhan Zhang
Journal:  Cancer Treat Rev       Date:  2012-05-29       Impact factor: 12.111

7.  Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line.

Authors:  Stefania Catalano; Stefania Marsico; Cinzia Giordano; Loredana Mauro; Pietro Rizza; Maria Luisa Panno; Sebastiano Andò
Journal:  J Biol Chem       Date:  2003-05-06       Impact factor: 5.157

Review 8.  Vascular endothelial growth factor and its relationship to inflammatory mediators.

Authors:  Laura S Angelo; Razelle Kurzrock
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

9.  Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden.

Authors:  L Connelly; W Barham; H M Onishko; T Sherrill; L A Chodosh; T S Blackwell; F E Yull
Journal:  Oncogene       Date:  2010-11-15       Impact factor: 9.867

10.  Circulating levels of leptin, adiposity and breast cancer risk.

Authors:  M-H Wu; Y-C Chou; W-Y Chou; G-C Hsu; C-H Chu; C-P Yu; J-C Yu; C-A Sun
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more
  136 in total

1.  Small GTPase RBJ promotes cancer progression by mobilizing MDSCs via IL-6.

Authors:  Qiuyan Liu; Ha Zhu; Chaoxiong Zhang; Taoyong Chen; Xuetao Cao
Journal:  Oncoimmunology       Date:  2016-12-23       Impact factor: 8.110

2.  7,8-Dihydroxycoumarin exerts antitumor potential on DMBA-induced mammary carcinogenesis by inhibiting ERα, PR, EGFR, and IGF1R: involvement of MAPK1/2-JNK1/2-Akt pathway.

Authors:  Abhishek Kumar; Priyashree Sunita; Shivesh Jha; Shakti P Pattanayak
Journal:  J Physiol Biochem       Date:  2018-02-12       Impact factor: 4.158

Review 3.  Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy.

Authors:  Meng Lan; Wenping Lu; Tengteng Zou; Lihong Li; Fengjie Liu; Tiange Cai; Yu Cai
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

4.  Three dimensional engineered models to study hypoxia biology in breast cancer.

Authors:  Vaishali Aggarwal; Oshin Miranda; Paul A Johnston; Shilpa Sant
Journal:  Cancer Lett       Date:  2020-06-20       Impact factor: 8.679

5.  Discovery of two-level modular organization from matched genomic data via joint matrix tri-factorization.

Authors:  Jinyu Chen; Shihua Zhang
Journal:  Nucleic Acids Res       Date:  2018-07-06       Impact factor: 16.971

6.  Differential in vivo biodistribution of 131I-labeled exosomes from diverse cellular origins and its implication for theranostic application.

Authors:  Mohammad H Rashid; Thaiz F Borin; Roxan Ara; Kartik Angara; Jingwen Cai; Bhagelu R Achyut; Yutao Liu; Ali S Arbab
Journal:  Nanomedicine       Date:  2019-08-01       Impact factor: 5.307

7.  Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases.

Authors:  Zhuangwei Lv; Min Liu; Jinghui Shen; Dong Xiang; Yunfeng Ma; Yanhong Ji
Journal:  Exp Ther Med       Date:  2018-04-30       Impact factor: 2.447

8.  Hydroxyapatite mineral enhances malignant potential in a tissue-engineered model of ductal carcinoma in situ (DCIS).

Authors:  Frank He; Nora L Springer; Matthew A Whitman; Siddharth P Pathi; Yeonkyung Lee; Sunish Mohanan; Stephen Marcott; Aaron E Chiou; Bryant S Blank; Neil Iyengar; Patrick G Morris; Maxine Jochelson; Clifford A Hudis; Pragya Shah; Jennie A M R Kunitake; Lara A Estroff; Jan Lammerding; Claudia Fischbach
Journal:  Biomaterials       Date:  2019-09-11       Impact factor: 12.479

Review 9.  Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures.

Authors:  Olga Golubnitschaja; Manuel Debald; Kristina Yeghiazaryan; Walther Kuhn; Martin Pešta; Vincenzo Costigliola; Godfrey Grech
Journal:  Tumour Biol       Date:  2016-07-22

10.  Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.

Authors:  Alfeu Zanotto-Filho; Subapriya Rajamanickam; Eva Loranc; V Pragathi Masamsetti; Aparna Gorthi; July Carolina Romero; Sonal Tonapi; Rosangela Mayer Gonçalves; Robert L Reddick; Raymond Benavides; John Kuhn; Yidong Chen; Alexander J R Bishop
Journal:  Cancer Lett       Date:  2018-03-30       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.